Maninder Bedi, MD
Cardiovascular Disease · Weirton, WVNPI 1003851213
Payments from drug & device makers
Across 712 payments — averaging $467.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$148K
- Boston Scientific$127K
- Impulse Dynamics (USA) Inc.$14K
- Baylis Medical Company Inc$12K
- Abbott$10K
- Biosense Webster, Inc.$10K
- plus $13K from 32 others
What the payments were for
- Consulting fees$22,33210%
- Speaking & faculty fees$142,70062%
- Travel & lodging$40,95218%
- Food & beverage$24,23011%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 230 | $148,219 |
| Boston Scientific | 199 | $126,625 |
| Impulse Dynamics (USA) Inc. | 17 | $13,786 |
| Baylis Medical Company Inc | 8 | $11,561 |
| Abbott | 98 | $10,190 |
| Biosense Webster, Inc. | 15 | $9,529 |
| Biotronik Inc. | 26 | $5,853 |
| Sanofi-aventis U.S. LLC | 6 | $2,660 |
| Cook Incorporated | 2 | $704 |
| Kestra Medical Technology Services, Inc. | 11 | $618 |
| Atricure, Inc. | 5 | $526 |
| Irhythm Technologies, Inc. | 5 | $369 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $321 |
| E.r. Squibb & Sons, L.L.C. | 18 | $305 |
| AstraZeneca | 5 | $163 |
| Johnson & Johnson | 9 | $127 |
| Cook Medical LLC | 1 | $124 |
| Cvrx, Inc. | 4 | $121 |
| ZOLL Respicardia, Inc. | 1 | $118 |
| Edwards Lifesciences | 4 | $99 |
| Pfizer | 5 | $97 |
| Vektor Medical Inc. | 1 | $89 |
| Boehringer Ingelheim | 5 | $86 |
| Elutia, Inc. | 2 | $54 |
| Scpharmaceuticals Inc. | 3 | $52 |
| Alnylam Pharmaceuticals Inc. | 2 | $47 |
| Heartflow, Inc. | 1 | $42 |
| Novartis | 2 | $38 |
| Amgen | 2 | $30 |
| Shockwave Medical, Inc | 2 | $27 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Cardiva Medical, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $19 |
| United Therapeutics Corporation | 1 | $19 |
| Merck | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Bayer | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arctic Front$45,434
- GENERAL - THERAPIES$29,968
- Carto 3 System$9,012
- Carto Smarttouch$8,898
- Carto CFAE$8,898
- CartoSound$8,898
- InSync$8,421
- VersaCross Access Solution$3,462
- NRG needle$3,000
- VersaCross$3,000
- ACUITY$2,800
- Confirm Rx$2,750
- DISEASE STATE$2,544
- ENSITE PRECISION$2,278
- AVEIR$1,843
- Micra$1,436
- Watchman$1,130
- DiamondTemp$1,083
- WATCHMAN Access System$794
- Cook Medical Lead Management$704
How this compares
$332,721 in reported general payments places this provider in the 95th percentile of 100 cardiovascular disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,350 | $1,127,639 |
| XareltoRivaroxaban | 376 | $332,525 |
| Dofetilide | 598 | $115,643 |
| Propafenone Hcl ErPropafenone Hcl | 389 | $65,758 |
| EntrestoSacubitril/Valsartan | 40 | $41,280 |
| MultaqDronedarone Hcl | 33 | $32,716 |
| Flecainide Acetate | 544 | $19,071 |
| Amiodarone Hcl | 1,094 | $17,158 |
| Mexiletine Hcl | 142 | $11,688 |
| Metoprolol Succinate | 1,019 | $10,202 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 246 | $6,265 |
| Propafenone Hcl | 110 | $4,999 |
| Verapamil SrVerapamil Hcl | 44 | $4,215 |
| SotalolSotalol Hcl | 208 | $3,878 |
| Midodrine Hcl | 55 | $2,939 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $97 | $1,127,6391,350 claims |
| Johnson & JohnsonXarelto | $127 | $332,525376 claims |
| NovartisEntresto | $38 | $41,28040 claims |
| Sanofi-aventis U.S. LLCMultaq | $2,660 | $32,71633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 100 cardiovascular disease providers in West Virginia.
Other cardiovascular disease in Weirton
- Daniel JovanovichWeirton$18K
- Scott MillerCharleston$2.5M
- Sarah RinehartCharleston$676K
- Partho SenguptaMorgantown$326K
- Irfan ZebMorgantown$188K
- Esam BaryunHuntington$111K
- Anthony MoriseMorgantown$88K
- Kofi OseiHuntington$87K
- Ellen ThompsonHuntington$56K
- Mohammad YousafSouth Charleston$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.